CU20190113A7 - Composición farmacéutica con fines terapéuticos - Google Patents

Composición farmacéutica con fines terapéuticos

Info

Publication number
CU20190113A7
CU20190113A7 CU2019000113A CU20190113A CU20190113A7 CU 20190113 A7 CU20190113 A7 CU 20190113A7 CU 2019000113 A CU2019000113 A CU 2019000113A CU 20190113 A CU20190113 A CU 20190113A CU 20190113 A7 CU20190113 A7 CU 20190113A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
peptides
proteins
inflammatory
therapeutic purposes
Prior art date
Application number
CU2019000113A
Other languages
English (en)
Other versions
CU24626B1 (es
Inventor
Crespo Nashelly Esquivel
Hernández Yenela García
Raveiro Yanary Govin
Verdecia Mayelín Odelín
Martínez Yoel Perea
Capiro Rachel Rabago
Zamora Mary Carmen Reyes
Martínez Claudio Rodríguez
Oramas Diana Rosa Viera
Original Assignee
Centro Nac De Biopreparados
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Biopreparados filed Critical Centro Nac De Biopreparados
Priority to CU2019000113A priority Critical patent/CU24626B1/es
Priority to CA3165245A priority patent/CA3165245A1/en
Priority to CN202080097527.4A priority patent/CN115209908A/zh
Priority to MX2022007991A priority patent/MX2022007991A/es
Priority to EP20904540.0A priority patent/EP4129318A4/en
Priority to PCT/CU2020/050006 priority patent/WO2021129897A1/es
Publication of CU20190113A7 publication Critical patent/CU20190113A7/es
Publication of CU24626B1 publication Critical patent/CU24626B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención consiste en una composición farmacéutica basada en proteínas y péptidos que las componen con una concentración total de proteínas de 0,2 a 3 mg/ml o mg/g. Las proteínas y péptidos son combinados seleccionando una o varios pertenecientes al menos a dos grupos clasificados por su actividad sobre el organismo humano, entre ellas actividad antioxidante, sobre el sistema ubiquitino-proteosoma, antiinflamatoria y moduladora del sistema inmune, antimicrobiana y sobre la transcripción y síntesis de proteínas. A partir de la combinación de proteínas y péptidos se conforma una composición farmacéutica para su administración por vía intranasal, intramuscular, endovenosa, oral o sublingual para el tratamiento de enfermedades del sistema nervioso central y periférico, autoinmunes e inflamatorias, infecciosas, inmunodeficiencias primarias y secundarias y cáncer.</p>
CU2019000113A 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana CU24626B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CU2019000113A CU24626B1 (es) 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana
CA3165245A CA3165245A1 (en) 2019-12-26 2020-11-23 Protein-based pharmaceutical composition with neuroprotective, immunomodulating, anti-inflammatory and antimicrobial activity
CN202080097527.4A CN115209908A (zh) 2019-12-26 2020-11-23 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物
MX2022007991A MX2022007991A (es) 2019-12-26 2020-11-23 Composicion farmaceutica a base de proteinas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana.
EP20904540.0A EP4129318A4 (en) 2019-12-26 2020-11-23 Protein-based pharmaceutical composition with neuroprotective, immunomodulating, anti-inflammatory and antimicrobial activity
PCT/CU2020/050006 WO2021129897A1 (es) 2019-12-26 2020-11-23 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoría y antimicrobiana

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2019000113A CU24626B1 (es) 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Publications (2)

Publication Number Publication Date
CU20190113A7 true CU20190113A7 (es) 2021-09-07
CU24626B1 CU24626B1 (es) 2022-11-07

Family

ID=76573804

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000113A CU24626B1 (es) 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Country Status (6)

Country Link
EP (1) EP4129318A4 (es)
CN (1) CN115209908A (es)
CA (1) CA3165245A1 (es)
CU (1) CU24626B1 (es)
MX (1) MX2022007991A (es)
WO (1) WO2021129897A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724233B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-13、制法和其药物组合物与用途
CA3230594A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
AU2022383744A1 (en) * 2021-11-02 2024-05-02 Enumita As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis
CN116350754A (zh) * 2023-05-16 2023-06-30 昆明理工大学 硫氧还蛋白-1在制备抑制皮质酮生成药物中的应用
JP2025063000A (ja) * 2023-10-03 2025-04-15 緑茵生技股▲ふん▼有限公司 ポリペプチド及びそれを血糖のコントロール及び／又は脂肪を減少するのに用いる用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2958198B2 (ja) 1992-09-28 1999-10-06 日誠マリン工業株式会社 鎮痛用医薬組成物
FR2741076B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US20030165492A1 (en) * 2000-06-08 2003-09-04 Alberto Panerai Method of treatment of alzheimer's disease with a protein extractable from mammalian organs
JP4925155B2 (ja) * 2002-06-10 2012-04-25 レドックス・バイオサイエンス株式会社 網膜神経細胞機能回復剤
CN1814276A (zh) 2005-01-31 2006-08-09 宝勒日 胸腺素β10的神经保护作用
US20090291884A1 (en) * 2006-11-02 2009-11-26 Michael Agadjanyan Proteins for use in diagnosing and treating infection and disease
CN101204578A (zh) * 2006-12-20 2008-06-25 干春玉 一种具有调节免疫、抗组织损伤及再生修复作用的胸腺素复合制剂
JP2011514383A (ja) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 改良されたベータチモシンフラグメント
AU2009274568A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN101693104A (zh) 2009-10-01 2010-04-14 厦门大学 胸腺5肽的新用途
ES2360333B1 (es) 2009-10-29 2012-05-04 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
ES2479815B1 (es) 2012-12-24 2015-05-06 Consejo Superior De Investigaciones Cientificas (Csic) Peptido neuroprotector asi como su uso en el tratamiento de enfermedades cerebrovasculares y otras patologias del snc
KR101745520B1 (ko) * 2015-05-29 2017-06-12 아주대학교산학협력단 신규한 tlr4 길항제
RU2678987C2 (ru) 2017-04-28 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Пептид для лечения болезни альцгеймера
WO2019018445A1 (en) 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES
CN109718363B (zh) 2017-10-26 2019-12-13 拜西欧斯（北京）生物技术有限公司 预防、缓解或治疗阿尔茨海默病的肽及其应用
CU24508B1 (es) 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl

Also Published As

Publication number Publication date
MX2022007991A (es) 2022-07-21
EP4129318A4 (en) 2024-05-29
CN115209908A (zh) 2022-10-18
CA3165245A1 (en) 2021-07-01
CU24626B1 (es) 2022-11-07
WO2021129897A1 (es) 2021-07-01
EP4129318A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
CU20190113A7 (es) Composición farmacéutica con fines terapéuticos
Kong et al. Macrophage polarization: a key event in the secondary phase of acute spinal cord injury
CL2023003883A1 (es) Restos de administración terapéutica novedosos y usos de estos
UY39856A (es) Inhibidores peptídicos del receptor de interleucina-23
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
ECSP22076862A (es) Compuestos antivirales y métodos para la administración de los mismos
PE20040474A1 (es) COMPOSICIONES QUE COMPRENDEN UN ANTICUERPO ANTI-TNFalfa Y OTRO FARMACO
BR112022019609A2 (pt) Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
EA202090573A1 (ru) Составы нирапариба
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
CY1115991T1 (el) Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες
Hamdani et al. Immuno-inflammatory markers of bipolar disorder: a review of evidence
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
MX2024015063A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades
MX2021012894A (es) Compuestos ciclicos de fosfato.
CO2022011183A2 (es) Conjugados de proteínas-compuestos antivirales
JP2014506231A5 (es)
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
WO2014136814A1 (ja) 新規ｃｔｌエピトープ５連結ペプチド
CA2996874A1 (en) Compositions and methods for the treatment of neurodamage
Raja et al. Therapeutic applications of cyanobacteria with emphasis on their economics
BR112015013215A2 (pt) proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
MX2019013819A (es) Oligopeptidos inhibitorios de la angiogenesis y de la funcion vascular.